期刊
JOURNAL OF THE AMERICAN HEART ASSOCIATION
卷 11, 期 4, 页码 -出版社
WILEY
DOI: 10.1161/JAHA.121.022376
关键词
glucagon-like peptide-1 receptor; heart failure; myocardial infarction; sodium-glucose transporter 2 inhibitors; type 2 diabetes
资金
- Department of Epidemiology, University of North Carolina at Chapel Hill, Gillings School of Global Public Health
- Cecil G. Sheps Center for Health Services Research, UNC
- Comparative Effectiveness Research Strategic Initiative of UNC's Clinical and Translational Science Award [UL1TR002489]
- UNC School of Medicine
This study evaluated the relative cardiovascular effectiveness of SGLT2i and GLP-1RA in routine care populations with atherosclerotic cardiovascular diseases (CVDs) or heart failure (HF). The results showed that SGLT2i reduced the risk of hospitalized HF in patients with a history of HF but no CVD. However, GLP-1RA was associated with lower occurrence of atherosclerotic CVD events in patients without prior CVD or HF.
Background Randomized trials demonstrate the cardioprotective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). We evaluated their relative cardiovascular effectiveness in routine care populations with a broad spectrum of atherosclerotic cardiovascular diseases (CVDs) or heart failure (HF). Methods and Results We identified Medicare beneficiaries from 2013 to 2017, aged >65 years, initiating SGLT2i (n=24 747) or GLP-1RA (n=22 596) after a 1-year baseline. On the basis of diagnoses during baseline, we classified patients into: (1) no HF or CVD, (2) HF but no CVD, (3) no HF but CVD, and (4) both HF and CVD. We identified hospitalized HF and atherosclerotic CVD outcomes from drug initiation until treatment changes, death, or disenrollment. We estimated propensity score-weighted 2-year risk ratios (RRs) and risk differences, accounting for measured confounding, informative censoring, and competing risk. In patients with no CVD or HF, SGLT2i reduced the hospitalized HF risk compared with GLP-1RA (propensity score-weighted RR, 0.65; 95% CI, 0.43-0.96). The association was strongest in those who had HF but no CVD (RR, 0.48; 95% CI, 0.25-0.85). The combined myocardial infarction, stroke, and mortality outcome risk was slightly higher for SGLT2i compared with GLP-1RA in those without CVD or HF (RR, 1.31; 95% CI, 1.09-1.56). The association was favorable toward SGLT2i in subgroups with a history of HF. Conclusions SGLT2i reduced the cardiovascular risk versus GLP-1RA in patients with a history of HF but no CVD. Atherosclerotic CVD events were less frequent with GLP-1RA in those without prior CVD or HF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据